BR112021025948A2 - Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes - Google Patents

Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes

Info

Publication number
BR112021025948A2
BR112021025948A2 BR112021025948A BR112021025948A BR112021025948A2 BR 112021025948 A2 BR112021025948 A2 BR 112021025948A2 BR 112021025948 A BR112021025948 A BR 112021025948A BR 112021025948 A BR112021025948 A BR 112021025948A BR 112021025948 A2 BR112021025948 A2 BR 112021025948A2
Authority
BR
Brazil
Prior art keywords
negative
acid
gram
fast bacteria
chp
Prior art date
Application number
BR112021025948A
Other languages
English (en)
Portuguese (pt)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of BR112021025948A2 publication Critical patent/BR112021025948A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14211—Microviridae
    • C12N2795/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021025948A 2019-07-05 2020-07-02 Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes BR112021025948A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962870908P 2019-07-05 2019-07-05
US201962892783P 2019-08-28 2019-08-28
US201962911900P 2019-10-07 2019-10-07
US201962948052P 2019-12-13 2019-12-13
US202062964743P 2020-01-23 2020-01-23
PCT/US2020/040714 WO2021007107A1 (en) 2019-07-05 2020-07-02 Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria

Publications (1)

Publication Number Publication Date
BR112021025948A2 true BR112021025948A2 (pt) 2022-02-08

Family

ID=74114204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025948A BR112021025948A2 (pt) 2019-07-05 2020-07-02 Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes

Country Status (11)

Country Link
US (1) US20220401514A1 (cg-RX-API-DMAC7.html)
EP (1) EP3993821A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022539383A (cg-RX-API-DMAC7.html)
KR (1) KR20220029746A (cg-RX-API-DMAC7.html)
CN (1) CN114401735A (cg-RX-API-DMAC7.html)
AU (1) AU2020310107A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025948A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145990A1 (cg-RX-API-DMAC7.html)
IL (1) IL289412A (cg-RX-API-DMAC7.html)
MX (1) MX2021015563A (cg-RX-API-DMAC7.html)
WO (1) WO2021007107A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
WO2020139890A1 (en) * 2018-12-27 2020-07-02 Johnson & Johnson Consumer Inc. Device and method for selective application of topical composition using dynamic threshold values
KR20230047155A (ko) 2020-08-03 2023-04-06 존슨 앤드 존슨 컨수머 인코포레이티드 눈밑 브라이트닝을 부여하기 위한 화장 조성물의 선택적 도포용 시스템 및 방법
CA3213352A1 (en) * 2021-03-26 2022-09-29 Raymond Schuch Amurins, lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
CN121445856B (zh) * 2025-10-24 2026-06-23 中国农业科学院生物技术研究所 溶菌酶及其衍生的抗菌肽和在制备抑菌药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741697A (en) * 1995-11-30 1998-04-21 University Of Rochester Bacteriophage of chlamydia psittaci
CA2447823A1 (en) * 2001-05-23 2002-11-28 The University Of British Columbia Diagnosis of vascular disease susceptibility using bacteriophage phi-cpn1 host chlamydia
PL2445515T3 (pl) * 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
WO2019191633A2 (en) * 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF

Also Published As

Publication number Publication date
EP3993821A1 (en) 2022-05-11
CN114401735A (zh) 2022-04-26
CA3145990A1 (en) 2021-01-14
IL289412A (en) 2022-02-01
US20220401514A1 (en) 2022-12-22
WO2021007107A1 (en) 2021-01-14
JP2022539383A (ja) 2022-09-08
EP3993821A4 (en) 2023-07-19
AU2020310107A1 (en) 2022-01-20
KR20220029746A (ko) 2022-03-08
MX2021015563A (es) 2022-03-17

Similar Documents

Publication Publication Date Title
AU2019222918B2 (en) Antimicrobial peptides and methods of use thereof
MX2021015563A (es) Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes.
Sinha et al. Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein
Le et al. Intracellular targeting mechanisms by antimicrobial peptides
US11690899B2 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
MX2020010071A (es) Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
Lee et al. Tissue expression and antibacterial activity of host defense peptides in chicken
Dawson et al. Properties and applications of antimicrobial peptides in biodefense against biological warfare threat agents
MX2020008860A (es) Lisinas plyss2 modificadas y sus usos.
KR101896927B1 (ko) 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 1 및 그의 조성물
US20250288652A1 (en) Bacteriophage lysine, chimera thereof and application thereof
Singh et al. A non-pediocin low molecular weight antimicrobial peptide produced by Pediococcus pentosaceus strain IE-3 shows increased activity under reducing environment
EA201990856A1 (ru) Новые противомикробные агенты против бактерий enterococcus
Malik et al. In vivo efficacy of anuran trypsin inhibitory peptides against staphylococcal skin infection and the impact of peptide cyclization
WO2024256710A3 (en) Engineered lysin polypeptide constructs active against gram-negative bacteria
US20160022832A1 (en) Proteas stabilized antibacterial peptides for s. aureus
KR20180052181A (ko) 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 2 및 그의 조성물
RU2022100889A (ru) Вакцинные конструкты и их применения против инфекций стафилококка
US20250101062A1 (en) Antimicrobial peptides
AU2004212179A1 (en) Antimicrobial agents from Streptococcus mitis and Streptococcus oralis
CN106749534B (zh) 一种许氏平鮋抗菌肽bs20及其应用
WO2024016011A3 (en) Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
US10150795B2 (en) Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same
Georgieva Short peptide analogs of LfcinB synthesized by Solid Phase Peptide Synthesis as an alternative to global microbial resistance
JP2019510519A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2840 DE 10/06/2025.